Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

(2021) Dan Turner et al.   GASTROENTEROLOGY

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

(2020) Yan Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease

(2020) Erwin Dreesen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Linked Pharmacometric‐Pharmacoeconomic Modelling and Simulation in Clinical Drug Development

(2020) Daniel Hill‐McManus et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

(2019) Bram Verstockt et al.   Journal of Crohns & Colitis

Mo1887 – Ustekinumab Endoscopic Response At Week 16 is Associated with Early Normalization of Fecal Calprotectin After Induction

(2019) Renske W. Pauwels et al.   GASTROENTEROLOGY

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients

(2018) J C Marini et al.   Journal of Crohns & Colitis

Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot

(2018) Karien Bloem et al.   Bioanalysis

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

(2018) Paul Rutgeerts et al.   GASTROENTEROLOGY

768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI

(2016) William Sandborn et al.   GASTROENTEROLOGY

OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1

(2016) B Feagan et al.   GUT

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα

(2016) William Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

(2016) Thomas Van Stappen et al.   Clinical and Translational Gastroenterology

C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

(2015) Mahmoud H Mosli et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biomarkers of Inflammation in Inflammatory Bowel Disease

(2015) Bruce E. Sands   GASTROENTEROLOGY

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease

(2013) Clas-Göran af Björkesten et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

(2012) Geert DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis

(2011) Y.W. Zhu et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

The use of ustekinumab in autoimmune disease

(2010) Caitriona Ryan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings

(2007) Taina Sipponen et al.   INFLAMMATORY BOWEL DISEASES